Amundi Pioneer Asset Management Inc. Buys 5,492 Shares of Thermo Fisher Scientific Inc. (TMO)

Amundi Pioneer Asset Management Inc. raised its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,247,958 shares of the medical research company’s stock after buying an additional 5,492 shares during the period. Thermo Fisher Scientific accounts for approximately 1.4% of Amundi Pioneer Asset Management Inc.’s portfolio, making the stock its 13th biggest holding. Amundi Pioneer Asset Management Inc. owned 0.56% of Thermo Fisher Scientific worth $425,313,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Winslow Capital Management LLC increased its stake in shares of Thermo Fisher Scientific by 25.0% in the first quarter. Winslow Capital Management LLC now owns 2,198,174 shares of the medical research company’s stock worth $337,639,000 after purchasing an additional 439,847 shares during the period. Rosenblum Silverman Sutton S F Inc. CA increased its stake in shares of Thermo Fisher Scientific by 1.6% in the first quarter. Rosenblum Silverman Sutton S F Inc. CA now owns 43,813 shares of the medical research company’s stock worth $6,730,000 after purchasing an additional 669 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of Thermo Fisher Scientific by 2.1% in the first quarter. Dimensional Fund Advisors LP now owns 2,835,460 shares of the medical research company’s stock worth $435,527,000 after purchasing an additional 57,480 shares during the period. Caisse DE Depot ET Placement DU Quebec increased its stake in shares of Thermo Fisher Scientific by 4.3% in the first quarter. Caisse DE Depot ET Placement DU Quebec now owns 901,182 shares of the medical research company’s stock worth $138,572,000 after purchasing an additional 37,400 shares during the period. Finally, Johnson Financial Group Inc. increased its stake in shares of Thermo Fisher Scientific by 2.5% in the first quarter. Johnson Financial Group Inc. now owns 1,619 shares of the medical research company’s stock worth $249,000 after purchasing an additional 39 shares during the period. Institutional investors own 86.16% of the company’s stock.

Thermo Fisher Scientific Inc. (NYSE:TMO) remained flat at $$189.49 during mid-day trading on Wednesday. The stock had a trading volume of 1,301,400 shares, compared to its average volume of 1,563,304. Thermo Fisher Scientific Inc. has a 52-week low of $139.88 and a 52-week high of $201.20. The firm has a market capitalization of $75,984.62, a price-to-earnings ratio of 20.82, a P/E/G ratio of 1.74 and a beta of 1.06. The company has a quick ratio of 0.81, a current ratio of 1.26 and a debt-to-equity ratio of 0.85.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, October 25th. The medical research company reported $2.31 earnings per share for the quarter, beating analysts’ consensus estimates of $2.24 by $0.07. The company had revenue of $5.12 billion for the quarter, compared to the consensus estimate of $5.03 billion. Thermo Fisher Scientific had a return on equity of 15.94% and a net margin of 11.73%. The company’s quarterly revenue was up 13.9% on a year-over-year basis. During the same period in the previous year, the business earned $2.03 earnings per share. equities analysts predict that Thermo Fisher Scientific Inc. will post 9.36 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Monday, January 15th. Shareholders of record on Friday, December 15th will be issued a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a yield of 0.32%. The ex-dividend date is Thursday, December 14th. Thermo Fisher Scientific’s payout ratio is 10.19%.

A number of equities analysts have recently commented on the company. Jefferies Group reiterated a “hold” rating and issued a $195.00 price objective on shares of Thermo Fisher Scientific in a research note on Thursday, September 28th. Goldman Sachs Group assumed coverage on Thermo Fisher Scientific in a research note on Tuesday, September 26th. They issued a “buy” rating and a $225.00 price objective on the stock. Barclays reiterated an “overweight” rating and issued a $215.00 price objective (up from $200.00) on shares of Thermo Fisher Scientific in a research note on Monday, September 25th. Leerink Swann reiterated an “outperform” rating and issued a $200.00 price objective (down from $216.00) on shares of Thermo Fisher Scientific in a research note on Monday, December 4th. Finally, Argus reiterated a “buy” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, August 22nd. They noted that the move was a valuation call. One investment analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $205.21.

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 50,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $188.39, for a total transaction of $9,419,500.00. Following the sale, the chief executive officer now directly owns 252,577 shares of the company’s stock, valued at $47,582,981.03. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.49% of the stock is currently owned by insiders.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this piece of content on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.thelincolnianonline.com/2017/12/13/amundi-pioneer-asset-management-inc-buys-5492-shares-of-thermo-fisher-scientific-inc-tmo.html.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply